Aug 31, 2013 by Dave WilliamsonFallout From the NFL's Concussion SettlementWhy the National Football League's $765 million deal is a win for the league and retired players.
Aug 31, 2013 by Dave WilliamsonIs this Key Obamacare Pillar in Jeopardy?A large insurer is pulling out of the state-based exchanges.
Aug 31, 2013 by Dave Williamson and Max MacalusoWhy This Flagship HIV Drug Is at RiskWhy declining future Atripla sales could be a good thing for Gilead.
Aug 30, 2013 by Dave Williamson and Max MacalusoCrowning the New King of BiotechWhat makes Gilead Sciences the leader.
Aug 20, 2013 by Dave WilliamsonAn Insurance Crackdown Warning Shot Is Cigna's policy change just another sign of things to come from managed-care companies
Aug 20, 2013 by Dave WilliamsonSurprising Side Effects Suspend Popular Animal Food AdditiveThe thin line between animal health and harm.
Aug 19, 2013 by Dave Williamson1 Biotech Fast-Tracked to FailureGTx collapsed 65% after a failed phase 3 drug trial.
Aug 18, 2013 by Dave Williamson and Alison SouthwickObamacare and the Patent Cliff Reshaping an IndustryMajor upheaval in the health-care business is fueling M&A as companies try to adapt to a new envrionment.
Aug 18, 2013 by Dave Williamson and Alison SouthwickThe Best Way to Play the Biotech IPO BoomWhy investors should think like a Big Pharma and not a short-term trader.
Aug 18, 2013 by Dave WilliamsonAnother Day, Another Shocking Obamacare DelayThis time, the out-of-pocket payment cap hits a one-year delay.
Aug 18, 2013 by Dave Williamson and Max MacalusoDoes Johnson & Johnson Have a Growth Problem?Taking a closer look at J&J's most important division
Aug 15, 2013 by Dave Williamson and Max MacalusoBreaking Down J&J's Fastest Growing SegmentWhy investors are excited about Johnson & Johnson.
Aug 15, 2013 by Dave WilliamsonWho Should Buy this Cancer-Fighting CompanyOnyx looks to be closing in on a deal with Amgen, but is it the best fit among rumored interested parties?
Aug 15, 2013 by Dave Williamson and Max MacalusoEli Lilly's Surprising Lung Cancer Success StoryHow a drug that few believed in came back and passed its phase 3 trials.
Aug 11, 2013 by Dave Williamson and Max MacalusoEli Lilly's Earnings Made EasyEverything investors need to know.
Aug 11, 2013 by Dave WilliamsonDown 20%: Another Dendreon Earnings DisasterIn what is quickly becoming a tradition like no other, Dendreon shares plunge on another earnings report.
Aug 11, 2013 by Dave Williamson2 Very Real Threats to ObamacareWhy Twitter opinion doesn't matter, but participation and security could affect the Affordable Care Act's success.
Aug 11, 2013 by Dave Williamson and Max MacalusoMerck's Earnings Made EasyEverything Investors need to know about Merck's second-quarter results.
Aug 11, 2013 by Dave Williamson and Max MacalusoBristol-Myers Squibb's Earnings Made EasyEverything investors need to learn about the Big Pharma company's second-quarter results.
Aug 9, 2013 by Dave Williamson and Max MacalusoPfizer's Earnings Made EasyEverything investors need to know about Pfizer's second-quarter results.
